ropivacaine

Ropivacaine is a long-acting amide-type local anesthetic, primarily available as the pure S-enantiomer. It acts by reversibly blocking sodium ion influx through voltage-gated sodium channels in nerve cell membranes, thereby inhibiting nerve impulse conduction and producing local anesthesia and analgesia. Compared to bupivacaine, ropivacaine has lower lipid solubility and reduced cardiotoxicity, making it safer for use in regional anesthesia including epidural, spinal (subarachnoid), peripheral nerve blocks, and infiltration anesthesia. It is widely used for surgical anesthesia as well as acute pain management such as postoperative or labor analgesia[1][2][4][5]. The drug was developed to provide a safer alternative to bupivacaine after reports of cardiac arrest associated with the latter[1][2]. Ropivacaine’s clinical advantages include sensory-motor separation at low concentrations (providing analgesia with minimal motor block) and frequency-dependent blockade favoring C-fibers over A-fibers[2].

Brand names

Naropin

Other names

罗哌卡因Ropivacaine hydrochloride盐酸罗哌卡因